Nanoparticle delivery of diphtheria toxin-encoding DNA selectively expressed in ovarian cancer cells reduced the burden of ovarian tumors in mice. Researchers expect this therapy could be tested in humans within 18 to 24 months, according to a report in Cancer Research. Read the press release.
Download a video interview (80.8 MB file; duration 4:53) of lead researcher Janet Sawicki, Ph.D. (requires QuickTime to view).
Watch the interview below:
Subscribe to the AACR RSS News Feed.
Page updated: Sept. 3, 2009